Repository logo
 
Publication

COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA.1/BA.2 lineages among adults and adolescents in a multicentre primary care study, Europe, December 2021 to June 2022

2024-03-28Journal article Open access
Simple item page
dc.contributor.authorLanièce Delaunay, Charlotte
dc.contributor.authorMartínez-Baz, Iván
dc.contributor.authorSève, Noémie
dc.contributor.authorDomegan, Lisa
dc.contributor.authorMazagatos, Clara
dc.contributor.authorBuda, Silke
dc.contributor.authorMeijer, Adam
dc.contributor.authorKislaya, Irina
dc.contributor.authorPascu, Catalina
dc.contributor.authorCarnahan, AnnaSara
dc.contributor.authorOroszi, Beatrix
dc.contributor.authorIlić, Maja
dc.contributor.authorMaurel, Marine
dc.contributor.authorMelo, Aryse
dc.contributor.authorSandonis Martín, Virginia
dc.contributor.authorTrobajo-Sanmartín, Camino
dc.contributor.authorEnouf, Vincent
dc.contributor.authorMcKenna, Adele
dc.contributor.authorPérez-Gimeno, Gloria
dc.contributor.authorGoerlitz, Luise
dc.contributor.authorde Lange, Marit
dc.contributor.authorRodrigues, Ana Paula
dc.contributor.authorLazar, Mihaela
dc.contributor.authorLatorre-Margalef, Neus
dc.contributor.authorTúri, Gergő
dc.contributor.authorCastilla, Jesús
dc.contributor.authorFalchi, Alessandra
dc.contributor.authorBennett, Charlene
dc.contributor.authorGallardo, Virtudes
dc.contributor.authorDürrwald, Ralf
dc.contributor.authorEggink, Dirk
dc.contributor.authorGuiomar, Raquel
dc.contributor.authorPopescu, Rodica
dc.contributor.authorRiess, Maximilian
dc.contributor.authorHorváth, Judit Krisztina
dc.contributor.authorCasado, Itziar
dc.contributor.authorGarcía, M. del Carmen
dc.contributor.authorHooiveld, Mariëtte
dc.contributor.authorMachado, Ausenda
dc.contributor.authorBacci, Sabrina
dc.contributor.authorKaczmarek, Marlena
dc.contributor.authorKissling, Esther
dc.date.accessioned2025-01-29T16:43:25Z
dc.date.available2025-01-29T16:43:25Z
dc.date.issued2024-03-28
dc.description.abstractBackground: Scarce European data in early 2021 suggested lower vaccine effectiveness (VE) against SARS-CoV-2 Omicron lineages than previous variants. Aim: We aimed to estimate primary series (PS) and first booster VE against symptomatic BA.1/BA.2 infection and investigate potential biases. Methods: This European test-negative multicentre study tested primary care patients with acute respiratory symptoms for SARS-CoV-2 in the BA.1/BA.2-dominant period. We estimated PS and booster VE among adults and adolescents (PS only) for all products combined and for Comirnaty alone, by time since vaccination, age and chronic condition. We investigated potential bias due to correlation between COVID-19 and influenza vaccination and explored effect modification and confounding by prior SARS-CoV-2 infection. Results: Among adults, PS VE was 37% (95% CI: 24–47%) overall and 60% (95% CI: 44–72%), 43% (95% CI: 26–55%) and 29% (95% CI: 13–43%) < 90, 90–179 and ≥ 180 days post vaccination, respectively. Booster VE was 42% (95% CI: 32–51%) overall and 56% (95% CI: 47–64%), 22% (95% CI: 2–38%) and 3% (95% CI: −78% to 48%), respectively. Primary series VE was similar among adolescents. Restricting analyses to Comirnaty had little impact. Vaccine effectiveness was higher among older adults. There was no signal of bias due to correlation between COVID-19 and influenza vaccination. Confounding by previous infection was low, but sample size precluded definite assessment of effect modification. Conclusion: Primary series and booster VE against symptomatic infection with BA.1/BA.2 ranged from 37% to 42%, with similar waning post vaccination. Comprehensive data on previous SARS-CoV-2 infection would help disentangle vaccine- and infection-induced immunity.pt_PT
dc.description.abstractKey public health message: - What did you want to address in this study and why? COVID-19 vaccine effectiveness can vary across populations and periods depending on multiple factors including the SARS-CoV-2 variants circulating, the time since last vaccination and the proportion of people who have been recently infected. We estimated the effectiveness of primary series and first booster vaccination against symptomatic infection with Omicron lineages BA.1 and BA.2 in a European study in 10 countries, up to June 2022. - What have we learnt from this study? The overall effectiveness of primary series vaccination and booster vaccination was around 40%, meaning that the risk of symptomatic COVID-19 was 40% lower among vaccinated people than among unvaccinated people. Vaccines provided lower protection against symptomatic infection with BA.1 and BA.2 than with previously circulating variants (e.g. Delta), and this protection decreased with time. - What are the implications of your findings for public health? Our results suggest that the timing of COVID-19 vaccination is key: vaccines should be administered in the weeks preceding periods of high SARS-CoV-2 circulation, and adapted vaccines could be considered. Primary series and booster vaccination had similar effectiveness, therefore if may be sufficient to estimate VE by time since last dose among those who received at least primary series vaccination, rather than by number of doses.por
dc.description.sponsorshipThis project has received funding from the European Centre for Disease Prevention and Control within the framework contract ECDC/2021/019. This project has also received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003673.
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationEuro Surveill. 2024 Mar;29(13):2300403. doi: 10.2807/1560-7917.ES.2024.29.13.2300403
dc.identifier.doi10.2807/1560-7917.ES.2024.29.13.2300403pt_PT
dc.identifier.issn1560-7917
dc.identifier.pmid38551095
dc.identifier.urihttp://hdl.handle.net/10400.18/10321
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherEuropean Centre for Disease Prevention and Controlpt_PT
dc.relationECDC/2021/019
dc.relationMultidisciplinary European network for research, prevention and control of the COVID-19 Pandemic
dc.relation.hasversionhttps://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2024.29.13.2300403
dc.relation.publisherversionhttps://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2024.29.13.2300403pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectVacina COVID-19pt_PT
dc.subjectVEBIS-LOT5pt_PT
dc.subjectCOVID-19
dc.subjectSARS-CoV-2
dc.subjectSARS-CoV-2 BA.1/BA.2pt_PT
dc.subjectTest-negative Design
dc.subjectVaccine Effectiveness
dc.subjectSymptomatic Infection
dc.subjectEfetividadept_PT
dc.subjectCuidados de Saúdept_PT
dc.titleCOVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA.1/BA.2 lineages among adults and adolescents in a multicentre primary care study, Europe, December 2021 to June 2022pt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.awardTitleMultidisciplinary European network for research, prevention and control of the COVID-19 Pandemic
oaire.awardURIinfo:eu-repo/grantAgreement/EC/H2020/101003673/EU
oaire.citation.issue13pt_PT
oaire.citation.startPage2300403
oaire.citation.titleEurosurveillancept_PT
oaire.citation.volume29pt_PT
oaire.fundingStreamH2020
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85
person.familyNameRodrigues
person.familyNameGuiomar
person.familyNameMachado
person.givenNameAna Paula
person.givenNameRaquel
person.givenNameAusenda
person.identifier.ciencia-idAE10-5FAB-7439
person.identifier.ciencia-id1217-6076-5D88
person.identifier.orcid0000-0003-2264-4723
person.identifier.orcid0000-0002-4563-6315
person.identifier.orcid0000-0002-1849-1499
project.funder.identifierhttp://doi.org/10.13039/501100008530
project.funder.nameEuropean Commission
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublicationc23c6d96-e605-424f-abbb-64d783c73939
relation.isAuthorOfPublication9743082d-bed6-4e5e-94f5-1d27bb037bb0
relation.isAuthorOfPublication544ad266-0c22-4a50-9ebc-86acc08d6666
relation.isAuthorOfPublication.latestForDiscovery9743082d-bed6-4e5e-94f5-1d27bb037bb0
relation.isProjectOfPublication7403e02d-5360-418c-8e37-687c3a1349f8
relation.isProjectOfPublication.latestForDiscovery7403e02d-5360-418c-8e37-687c3a1349f8

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
eurosurv-29-13_5.pdf
Size:
400.34 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

DEP - Artigos em revistas internacionais
DDI - Artigos em revistas internacionais
INSA - Artigos em revistas internacionais